EpiCan - CanPath - Canadian Partnership for Tomorrow’s Health

CanPath – Canadian Partnership for Tomorrow’s Health Search

About Us
- Purpose, Vision & Mission
  CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
- Our History
  The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
- Leadership & Governance
  Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
- National Coordinating Centre
  Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
- Regional Cohorts
  Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
- Funders & Supporters
  Learn more about the partner organizations that provide funding and in-kind support to CanPath.
- Frequently Asked Questions
  Find out how CanPath will improve the health of Canadians and more.
- Contact us
  How to reach CanPath by phone, email, in-person, or make a data access request.
Research
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Access Process
  The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
- Approved Projects & Studies
  CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
- Publications
  These publications are examples of research made possible with data from CanPath and its regional cohorts.
- Funding & Grant Opportunities
- COVID-19 Initiatives
  As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
- Student Dataset
  CanPath's Student Dataset provides students the unique opportunity to gain hands-on experience working with CanPath data.
- Collaborations
  The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
Participants
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Participant Snapshot
  Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
- Meet CanPath Participants
  Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
- COVID-19 Antibody Study FAQ
  CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
News & Events
CanPath Access Portal

EpiCan

Principal Investigator: Dr. Philip Awadalla

Affiliation: CanPath, Ontario Institute for Cancer Research

Start Year: 2015

Investigators: Dr. Philip Awadalla, Dr. Jeffrey R. Brook, Dr. Audrey Smargiassi, Dr. Perry Hystad, Dr. Markey Johnson, Dr. Julie Hussin

The Canadian Partnership for Tomorrow’s Health (CanPath) is the product of $150+ million dollar investment to create first class infrastructure to
support health research internationally. It is Canada’s largest population cohort with detailed data and biospecimens on 300,000+ adults.

CanPath leaders have teamed-up with scientists from a range of disciplines to enable a deeper understanding of how air pollution and the surroundings where people live interact with genes to influence cardiometabolic health. Existing data and resources are used to address essential questions for public health authorities, researchers, and health practitioners. The focus is on metabolic syndrome (MetS), a cluster of medical conditions common among aging adults: obesity, hypertension, high cholesterol, high blood sugar, and insulin resistance. Because people with MetS are more likely to develop diabetes and cardiovascular disease, MetS represents a substantial burden on
healthcare systems. MetS results from the interaction of genes, lifestyle and the environment, but these mechanisms are not well understood. This program aims to quantify the effect of air pollution and built environment on MetS, and map differences in DNA that impact gene expression, and see if their effect are modified by environmental factors.

Currently, no studies exist on the genetic and environmental risk factors of MetS at this scale, nor is there any program that has the infrastructure to return and share data with researchers to facilitate discovery.